Parkinson's disease (PD) is a progressive neurological disorder that primarily affects movement. It is characterized by the degeneration of dopamine-producing neurons in the substantia nigra, a part of the brain that controls movement. This article provides a comprehensive overview of PD, its pathophysiology, clinical manifestations, diagnosis, and treatment options.
The primary pathological feature of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in striatal dopamine levels. This results in an imbalance between the excitatory and inhibitory pathways in the basal ganglia, causing the characteristic motor symptoms of PD. The presence of Lewy bodies, abnormal aggregates of the protein alpha-synuclein, is another hallmark of PD.
PD typically presents with motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms can include autonomic dysfunction, cognitive impairment, mood disorders, and sleep disturbances. The disease progression varies among individuals, with some experiencing rapid progression while others remain stable for several years.
Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and response to dopaminergic medication. Neuroimaging can be used to support the diagnosis but is not definitive. Treatment is symptomatic, with levodopa being the most effective medication. Other treatment options include dopamine agonists, MAO-B inhibitors, and deep brain stimulation for advanced cases.
Understanding the pathophysiology, clinical manifestations, and treatment options for Parkinson's disease is crucial for healthcare professionals. Despite the progress made in managing PD, there is still no cure, and the disease continues to pose significant challenges. Continued research and development in this field are necessary to improve the quality of life for individuals living with PD.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation